Daniel I Schlessinger, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Delphi Technique | 9 | 2022 | 798 | 1.500 |
Why?
|
| Endpoint Determination | 3 | 2017 | 599 | 1.450 |
Why?
|
| Cosmetic Techniques | 2 | 2020 | 140 | 1.140 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2023 | 557 | 1.120 |
Why?
|
| Dermatology | 3 | 2024 | 885 | 0.800 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 158 | 0.650 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 7970 | 0.650 |
Why?
|
| Research Design | 9 | 2024 | 6118 | 0.640 |
Why?
|
| Skin Neoplasms | 6 | 2024 | 5751 | 0.600 |
Why?
|
| Skin Aging | 2 | 2018 | 128 | 0.580 |
Why?
|
| Rejuvenation | 1 | 2017 | 94 | 0.560 |
Why?
|
| Hyaluronic Acid | 1 | 2020 | 493 | 0.560 |
Why?
|
| Lipectomy | 1 | 2023 | 118 | 0.410 |
Why?
|
| Face | 1 | 2017 | 1008 | 0.390 |
Why?
|
| Melanosis | 2 | 2022 | 85 | 0.370 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 1459 | 0.330 |
Why?
|
| Consensus | 5 | 2022 | 3023 | 0.280 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 2313 | 0.260 |
Why?
|
| Tetracaine | 1 | 2024 | 35 | 0.240 |
Why?
|
| Lichen Planus | 1 | 2023 | 67 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 4062 | 0.210 |
Why?
|
| Mohs Surgery | 1 | 2024 | 207 | 0.200 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 74 | 0.200 |
Why?
|
| Hemangioma, Capillary | 1 | 2021 | 62 | 0.190 |
Why?
|
| Cheek | 1 | 2020 | 63 | 0.180 |
Why?
|
| Alopecia | 1 | 2023 | 392 | 0.170 |
Why?
|
| Keratosis, Actinic | 1 | 2020 | 75 | 0.170 |
Why?
|
| Rhytidoplasty | 1 | 2018 | 62 | 0.150 |
Why?
|
| Advisory Committees | 1 | 2022 | 779 | 0.150 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2018 | 93 | 0.150 |
Why?
|
| Injections | 1 | 2020 | 842 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 2024 | 990 | 0.140 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 192 | 0.140 |
Why?
|
| Sterilization | 1 | 2017 | 134 | 0.140 |
Why?
|
| Bibliometrics | 1 | 2020 | 348 | 0.140 |
Why?
|
| Lidocaine | 2 | 2024 | 545 | 0.140 |
Why?
|
| Hemangioma | 1 | 2021 | 744 | 0.140 |
Why?
|
| Rosacea | 1 | 2016 | 53 | 0.140 |
Why?
|
| Quality of Life | 3 | 2022 | 13044 | 0.130 |
Why?
|
| Politics | 1 | 2022 | 798 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2022 | 64017 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2024 | 1073 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2020 | 1552 | 0.120 |
Why?
|
| Carbon Dioxide | 1 | 2018 | 1162 | 0.110 |
Why?
|
| Research Report | 1 | 2016 | 354 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2020 | 2766 | 0.100 |
Why?
|
| Anesthesia, Local | 1 | 2023 | 275 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2018 | 917 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10057 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1463 | 0.090 |
Why?
|
| Humans | 24 | 2024 | 752741 | 0.090 |
Why?
|
| Linear Models | 1 | 2020 | 5965 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2956 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3627 | 0.080 |
Why?
|
| Patient Participation | 1 | 2017 | 1464 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 1552 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2295 | 0.070 |
Why?
|
| Patch Tests | 1 | 2023 | 53 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4929 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 2812 | 0.050 |
Why?
|
| Scrotum | 1 | 2021 | 121 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20026 | 0.050 |
Why?
|
| Device Approval | 1 | 2022 | 164 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18460 | 0.050 |
Why?
|
| Biological Transport | 1 | 2024 | 2121 | 0.040 |
Why?
|
| Forehead | 1 | 2018 | 70 | 0.040 |
Why?
|
| Insufflation | 1 | 2018 | 66 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2024 | 12202 | 0.040 |
Why?
|
| Recurrence | 2 | 2020 | 8422 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 1611 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2018 | 1232 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 2043 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 2642 | 0.030 |
Why?
|
| Biopsy | 1 | 2023 | 6771 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2024 | 40939 | 0.020 |
Why?
|
| Pain | 1 | 2024 | 5040 | 0.020 |
Why?
|
| Adiposity | 1 | 2018 | 1823 | 0.020 |
Why?
|
| Female | 6 | 2024 | 385090 | 0.020 |
Why?
|
| Time Factors | 2 | 2020 | 40195 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 216054 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2018 | 6037 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 13364 | 0.010 |
Why?
|
| Male | 4 | 2024 | 354311 | 0.010 |
Why?
|
| United States | 2 | 2022 | 70772 | 0.010 |
Why?
|
| Pregnancy | 1 | 2022 | 29630 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35447 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 21146 | 0.010 |
Why?
|
| Aged | 2 | 2020 | 165629 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39223 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 216658 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 78758 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 53863 | 0.010 |
Why?
|